In the fast-evolving world of precision medicine, multi-omics is no longer a niche pursuit. Researchers and clinicians are increasingly layering genomics, proteomics, transcriptomics, and metabolomics to uncover the intricate workings of human biology. They turn raw data into tailored treatments for complex diseases like cancer and Alzheimer’s. This integration promises breakthroughs in clinical trials, where multi-omics profiles can predict patient responses with unprecedented accuracy. It shifts healthcare from one-size-fits-all to truly personalized care. The revolution feels electric. Yet beneath the promise lies a data deluge that’s reshaping the biotech landscape.
Continue reading Multi-Omics Goes Mainstream… But WhoOwns the Data?